217 related articles for article (PubMed ID: 32593280)
1. Lipid Nanoformulations in the Treatment of Neuropsychiatric Diseases: An Approach to Overcome the Blood Brain Barrier.
Rehman S; Nabi B; Pottoo FH; Baboota S; Ali J
Curr Drug Metab; 2020; 21(9):674-684. PubMed ID: 32593280
[TBL] [Abstract][Full Text] [Related]
2. Recent progress of drug nanoformulations targeting to brain.
Khan AR; Yang X; Fu M; Zhai G
J Control Release; 2018 Dec; 291():37-64. PubMed ID: 30308256
[TBL] [Abstract][Full Text] [Related]
3. Lipid-based nanocarrier efficiently delivers highly water soluble drug across the blood-brain barrier into brain.
Dutta L; Mukherjee B; Chakraborty T; Das MK; Mondal L; Bhattacharya S; Gaonkar RH; Debnath MC
Drug Deliv; 2018 Nov; 25(1):504-516. PubMed ID: 29426257
[TBL] [Abstract][Full Text] [Related]
4. Lipid-based nanoformulations in the treatment of neurological disorders.
Pottoo FH; Sharma S; Javed MN; Barkat MA; Harshita ; Alam MS; Naim MJ; Alam O; Ansari MA; Barreto GE; Ashraf GM
Drug Metab Rev; 2020 Feb; 52(1):185-204. PubMed ID: 32116044
[TBL] [Abstract][Full Text] [Related]
5. Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations.
Zorkina Y; Abramova O; Ushakova V; Morozova A; Zubkov E; Valikhov M; Melnikov P; Majouga A; Chekhonin V
Molecules; 2020 Nov; 25(22):. PubMed ID: 33202839
[TBL] [Abstract][Full Text] [Related]
6. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability.
Talegaonkar S; Bhattacharyya A
AAPS PharmSciTech; 2019 Feb; 20(3):121. PubMed ID: 30805893
[TBL] [Abstract][Full Text] [Related]
7. Navigating the Nose-to-Brain Route: A Systematic Review on Lipid-Based Nanocarriers for Central Nervous System Disorders.
Agosti E; Zeppieri M; Antonietti S; Battaglia L; Ius T; Gagliano C; Fontanella MM; Panciani PP
Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543223
[TBL] [Abstract][Full Text] [Related]
8. Analyzing Nanotheraputics-Based Approaches for the Management of Psychotic Disorders.
Annu ; Rehman S; Md S; Baboota S; Ali J
J Pharm Sci; 2019 Dec; 108(12):3757-3768. PubMed ID: 31499066
[TBL] [Abstract][Full Text] [Related]
9. Delivery of Antipsychotics with Nanoparticles.
Sun Y; Kang C; Liu F; Song L
Drug Dev Res; 2016 Nov; 77(7):393-399. PubMed ID: 27546713
[TBL] [Abstract][Full Text] [Related]
10. Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors.
Okur NÜ; Siafaka PI; Gökçe EH
Curr Pharm Biotechnol; 2021; 22(7):892-905. PubMed ID: 32753006
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier.
Sarkar A; Fatima I; Jamal QMS; Sayeed U; Khan MKA; Akhtar S; Kamal MA; Farooqui A; Siddiqui MH
Curr Drug Metab; 2017; 18(2):129-137. PubMed ID: 28088890
[TBL] [Abstract][Full Text] [Related]
12. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases.
Cacciatore I; Ciulla M; Fornasari E; Marinelli L; Di Stefano A
Expert Opin Drug Deliv; 2016 Aug; 13(8):1121-31. PubMed ID: 27073977
[TBL] [Abstract][Full Text] [Related]
13. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
14. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
15. Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate.
Yasir M; Gaur PK; Puri D; Shehkar P; Kumar SS
Curr Drug Deliv; 2018; 15(6):818-828. PubMed ID: 28545354
[TBL] [Abstract][Full Text] [Related]
16. Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs.
Nabi B; Rehman S; Baboota S; Ali J
AAPS PharmSciTech; 2019 Jan; 20(2):60. PubMed ID: 30623263
[TBL] [Abstract][Full Text] [Related]
17. Solid lipid nanoparticles as a drug delivery system to across the blood-brain barrier.
He H; Yao J; Zhang Y; Chen Y; Wang K; Lee RJ; Yu B; Zhang X
Biochem Biophys Res Commun; 2019 Nov; 519(2):385-390. PubMed ID: 31519326
[TBL] [Abstract][Full Text] [Related]
18. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.
Ali Khan A; Mudassir J; Mohtar N; Darwis Y
Int J Nanomedicine; 2013; 8():2733-44. PubMed ID: 23926431
[TBL] [Abstract][Full Text] [Related]
19. Lipid Nanocarriers for Neurotherapeutics: Introduction, Challenges, Blood-brain Barrier, and Promises of Delivery Approaches.
Aslam M; Javed MN; Deeb HH; Nicola MK; Mirza MA; Alam MS; Akhtar MH; Waziri A
CNS Neurol Disord Drug Targets; 2022; 21(10):952-965. PubMed ID: 34967302
[TBL] [Abstract][Full Text] [Related]
20. Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation.
Graverini G; Piazzini V; Landucci E; Pantano D; Nardiello P; Casamenti F; Pellegrini-Giampietro DE; Bilia AR; Bergonzi MC
Colloids Surf B Biointerfaces; 2018 Jan; 161():302-313. PubMed ID: 29096375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
